Sinequan

Insomnia, Neurotic depression, Depression + 8 more

Treatment

20 Active Studies for Sinequan

What is Sinequan

Doxepin

The Generic name of this drug

Treatment Summary

Doxepin is a drug prescribed to treat depression, anxiety, and insomnia. It is a type of medication known as a tertiary amine that helps to balance the levels of certain chemicals in the brain. Doxepin was first approved by the FDA in 1969 for the treatment of depression and later approved for the treatment of insomnia in 2010. It belongs to the same drug family as amitriptyline, clomipramine, desipramine, imipramine, nortriptyline, protriptyline, and trimipramine.

Sinequan

is the brand name

image of different drug pills on a surface

Sinequan Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Sinequan

Doxepin

1969

307

Effectiveness

How Sinequan Affects Patients

Doxepin is a type of antidepressant that works by decreasing the activity of the brain. It can also help with insomnia and anxiety. It may take two weeks for the antidepressant effects to show, but the sedative effects are immediate. At high doses, it can cause central nervous system depression and its anticholinergic and antiadrenergic effects can limit its efficacy.

How Sinequan works in the body

Doxepin works by blocking histamine receptors in the skin to reduce inflammation. It also works on the central nervous system to increase levels of serotonin and norepinephrine. This helps improve mood and reduce depression symptoms. Doxepin may also desensitize serotonin 1A receptors and beta-adrenergic receptors. It is believed to increase dopamine transmission in the frontal cortex which is thought to help improve mood.

When to interrupt dosage

The advocated dose of Sinequan is contingent upon the determined condition, for example Depression, Involutional, Mental Disorder, Organic and Insomnia. The dose can be found in the table below, based on the technique of delivery (e.g. Oral or Tablet - Oral).

Condition

Dosage

Administration

Insomnia

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Solution, Solution - Oral

Neurotic depression

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Solution, Solution - Oral

Depression

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Solution, Solution - Oral

Generalized Anxiety Disorder

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Solution, Solution - Oral

Neuropathic Pain

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Solution, Solution - Oral

Itching

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Solution, Solution - Oral

Depressive Disorder, Major

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Solution, Solution - Oral

Behcet Syndrome

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Solution, Solution - Oral

Alcoholism

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Solution, Solution - Oral

Depressive Disorder, Major

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Solution, Solution - Oral

Neurodermatitis

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Solution, Solution - Oral

Warnings

Sinequan has four contraindications and thus should not be taken when encountering any of the conditions shown in the following table.

Sinequan Contraindications

Condition

Risk Level

Notes

untreated narrow angle glaucoma

Do Not Combine

Pulse Frequency

Do Not Combine

Urinary Retention

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Doxepin may interact with Pulse Frequency

There are 20 known major drug interactions with Sinequan.

Common Sinequan Drug Interactions

Drug Name

Risk Level

Description

4-Methoxyamphetamine

Major

Doxepin may increase the vasopressor activities of 4-Methoxyamphetamine.

Acepromazine

Major

Doxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.

Aclidinium

Major

The risk or severity of adverse effects can be increased when Doxepin is combined with Aclidinium.

Alfuzosin

Major

Doxepin may increase the hypotensive activities of Alfuzosin.

Aripiprazole

Major

Doxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.

Sinequan Toxicity & Overdose Risk

Doxepin is toxic in high doses, with a lethal dose of 180mg/kg in mice and 147mg/kg in rats. Overdosing on doxepin can cause seizures, heart rhythm problems, loss of consciousness, low blood pressure, central nervous system depression, changes on an EKG, and even death. In fertility studies, doxepin was found to reduce the time of copulation, decrease the number of viable embryos, decrease litter size, and decrease sperm motility. There is no evidence that doxepin causes cancer or mutations.

image of a doctor in a lab doing drug, clinical research

Sinequan Novel Uses: Which Conditions Have a Clinical Trial Featuring Sinequan?

1020 active trials are being conducted to assess the potential of Sinequan in managing Generalized Anxiety Disorder, Atopic Dermatitis and Bipolar Disorder.

Condition

Clinical Trials

Trial Phases

Generalized Anxiety Disorder

194 Actively Recruiting

Not Applicable, Early Phase 1, Phase 2, Phase 4, Phase 3, Phase 1

Depressive Disorder, Major

0 Actively Recruiting

Insomnia

0 Actively Recruiting

Depression

306 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

Alcoholism

7 Actively Recruiting

Not Applicable, Phase 2, Phase 3

Neurotic depression

0 Actively Recruiting

Depressive Disorder, Major

0 Actively Recruiting

Itching

4 Actively Recruiting

Phase 3, Not Applicable, Early Phase 1

Behcet Syndrome

1 Actively Recruiting

Not Applicable

Neuropathic Pain

4 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Neurodermatitis

0 Actively Recruiting

Sinequan Reviews: What are patients saying about Sinequan?

5

Patient Review

8/30/2010

Sinequan for Itching

This medication has been a lifesaver for me on two different occasions when I've suffered from chronic urticaria. It's completely alleviated my problem when taken with other OTC antihistamines. I only need to take 10 mg each night for 3-4 weeks during flare-ups now. The main side effects I've experienced are dry mouth and an extreme drop in libido due to decreased lubrication.

5

Patient Review

1/17/2018

Sinequan for Nerve Pain

My neurologist prescribed this for me 15 years ago when I was 50 and suffering from peripheral neuropathy pain. It's been a godsend, allowing me to walk without pain.

4.7

Patient Review

7/29/2016

Sinequan for Anxiousness associated with Depression

Doxepin has been a game-changer for me. It's helped with my anxiety, depression, and insomnia. I have experienced dry mouth as a side effect; however, it hasn't been bad enough to make me want to stop taking the medication.

4.3

Patient Review

5/1/2010

Sinequan for Anxiousness associated with Depression

Sinequan has been an utter game-changer for me. I was struggling with anxiety and depression to the point where I rarely left my house, but this medication helped me get my life back. The only downside is that I've gained about 30 pounds since starting it.

3.7

Patient Review

10/8/2011

Sinequan for Anxious

This medication didn't do much for my constipation.

3

Patient Review

11/2/2011

Sinequan for Depression

I started taking this treatment two weeks ago. So far, I haven't seen a huge difference, but it takes time for medications to build up in your system so I'm hopeful.

2.3

Patient Review

9/24/2013

Sinequan for Depression

I'm still struggling with depression, and this medication hasn't been helping.

1.7

Patient Review

3/16/2014

Sinequan for Depression

This didn't help me at all and I had a lot of trouble sleeping.

1

Patient Review

3/26/2010

Sinequan for Bipolar Depression

The side effects of this medication were really terrible. I gained a lot of weight, felt groggy and irritable the next day, and would wake up in the middle of the night and eat everything in sight. I stopped taking it after only 8 months because it was making me so unhealthy.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about sinequan

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How much sinequan can you take for sleep?

"Adults should take 6 milligrams (mg) of the medication once a day. Older adults should take 3 mg of the medication once a day. The doctor may adjust the dose as needed."

Answered by AI

Is sinequan still prescribed?

"The brand name Sinequan is no longer available in the United States. However, generic forms are still available."

Answered by AI

What is the drug sinequan used for?

"This medication is used to improve mood, relieve tension and anxiety, help with sleep, and increase energy. It belongs to a class of medications called tricyclic antidepressants."

Answered by AI

Is doxepin a good sleeping pill?

"This results in improvement in depression or anxiety.

Doxepin is used to treat anxiety or depression and also to treating insomnia by increasing levels of certain chemicals in the brain, which improves depression or anxiety."

Answered by AI

Clinical Trials for Sinequan

Image of Cedars Sinai Medical Offices East Tower in Los Angeles, United States.

Active VR for Anxiety During ENT Procedures

18+
All Sexes
Los Angeles, CA

The purpose of this research is to evaluate whether active virtual reality reduces pain and anxiety more effectively than passive virtual reality during office-based ENT procedures. The main procedures include exposure to virtual reality (passive calming scenery or interactive puzzle game) via Paperplane Therapeutics software with VR headset or glasses during common in-office ENT procedures, participant self-report surveys (GAD-7, PHQ-9, PEG, VAS, SUDS, Likert, experience questions), and physician post-procedure survey. The study will enroll individuals 18 years or older who are scheduled to undergo common office-based ENT procedures (turbinate reduction, nasal debridement, balloon sinuplasty, radiofrequency ablation, nasal polypectomy, eustachian tube dilation, vocal fold injection, or subglottic steroid injection) at Cedars Sinai.

Waitlist Available
Has No Placebo

Cedars Sinai Medical Offices East Tower

Image of Washington University School of Medicine in St Louis, United States.

Psilocybin-Assisted Therapy for Depression

18+
All Sexes
St Louis, MO

Depression is the leading cause of disability worldwide, affecting an estimated 300 million people. Despite available treatments, response rates remain modest, and treatment resistance is common. Novel treatments are needed that act rapidly, produce lasting effects and work differently than existing antidepressants. In clinical trials, psilocybin has shown promise as a treatment for depression due to its rapid onset of antidepressant effects and sustained benefits. This study will use MRI scanning of the brain and other biological measures (biomarkers) to investigate how psilocybin affects brain activity and psychological flexibility before, during, and after receiving psilocybin in participants with depressive symptoms.

Phase 2
Waitlist Available

Washington University School of Medicine

Have you considered Sinequan clinical trials?

We made a collection of clinical trials featuring Sinequan, we think they might fit your search criteria.
Go to Trials
Image of Imperial Valley College in Imperial, United States.

Cognitive Behavioral Therapy for Mental Health

18+
All Sexes
Imperial, CA

The goal of this study is to understand why certain treatments help people reduce repetitive negative thinking (RNT), which is common in many mental health problems. We want to: 1. Figure out what actually causes repetitive negative thinking to decrease when people use cognitive-behavioral therapy (CBT). 2. Find out which parts of RNT-focused CBT are the most important - the parts that truly make a difference in reducing RNT. The main result we will look at is how much a person's repetitive negative thought patterns change from the start of the study to the end of treatment (16 weeks). We will measure this using the Perseverative Thinking Questionnaire at baseline and week 16.

Waitlist Available
Has No Placebo

Imperial Valley College

Image of The Korean Association of West Florida in Tampa, United States.

Mobile App Mindfulness for Mental Health

18+
All Sexes
Tampa, FL

The goal of this clinical trial (single-arm pilot trial) is to learn whether a mobile application-based mindfulness intervention can improve mental health outcomes in older Korean immigrants aged 60 years and older. The main questions it aims to answer are whether the 8-week mobile app-based mindfulness intervention is feasible and acceptable, as indicated by recruitment, retention, and adherence rates, and whether participation in the intervention leads to improvements in positive psychological well-being (e.g., positive affect, optimism, life engagement, and mindfulness) and reductions in adverse mental health outcomes (e.g., anxiety, depressive symptoms, and perceived stress). Participants will complete baseline and post-intervention assessments, receive training on how to use the mobile mindfulness application, engage with the app for approximately 8 weeks (recommended 10-15 minutes per day), and participate in weekly check-ins to support engagement and address any challenges encountered during the intervention.

Waitlist Available
Has No Placebo

The Korean Association of West Florida (+1 Sites)

Soonhyung Kwon

Have you considered Sinequan clinical trials?

We made a collection of clinical trials featuring Sinequan, we think they might fit your search criteria.
Go to Trials
Image of Michael E. DeBakey VA Medical Center, Houston, TX in Houston, United States.

Behavioral Activation-Guided Self-Help for Depression

18+
All Sexes
Houston, TX

Symptoms of depression are highly prevalent among Veterans. However, fewer than 30% of individuals with these symptoms receive any psychotherapy in the Veterans Health Administration (VHA). This is due to many factors, which may include provider availability and patient preferences. Guided self-help (GSH), which involves coaching sessions with patients who are following a fully developed self-help program, has the potential to increase access to care for these Veterans, particularly if implemented within a stepped care model of mental health treatment delivery and if delivered by a diverse set of providers. The VHA's primary care-mental health integration (PCMHI) service, which focuses on short courses of care for mild to moderate symptoms, may be an ideal place in which to deploy GSH. The current project seeks conduct a pilot randomized trial of a GSH program for depression adapted for PCMHI based on behavioral activation.

Waitlist Available
Has No Placebo

Michael E. DeBakey VA Medical Center, Houston, TX

Maribel Plasencia, BA MS PhD

Image of Vanderbilt University Medical Center in Nashville, United States.

Cognitive Training + tDCS for Depression

18+
All Sexes
Nashville, TN

The goal of this clinical trial is to learn if a combination of non-drug treatments works to benefit memory, thinking, and brain functioning in older individuals with recurrent depression. The non-drug approaches the investigators are studying include transcranial direct current stimulation (tDCS) and computerized cognitive training. tDCS uses small currents of electricity on the forehead to potentially stimulate your brain's ability to process and learn. Computerized cognitive training uses tablet games to improve memory and thinking. In this study, two different cognitive training programs are being investigated, both of which are stimulating and designed to engage brain activity. One that is believed to be a specific treatment for depression, while the other provides extra stimulation for the brain that is non-specific. Two different tDCS parameters - active stimulation and sham (or placebo) stimulation - are also being investigated. Participants will be randomized to one of three study groups: 1. Depression cognitive training treatment with active brain stimulation 2. Depression cognitive training treatment with sham brain stimulation 3. Non-specific cognitive training treatment with sham brain stimulation The main questions this clinical trial aims to answer are: * Does "depression cognitive training treatment with active brain stimulation" benefit thinking and memory more so than the other treatments? * Does "depression cognitive training treatment with active brain stimulation" benefit brain functioning more so than the other treatments? Participants will: * Complete several baseline and post-intervention visits at the research center for checkups and tests over the course of 3-4 months. * Visit the research center daily for 4 weeks to complete their assigned treatment.

Waitlist Available
Has No Placebo

Vanderbilt University Medical Center

Image of UC San Diego Health Psychiatry in San Diego, United States.

Medi-TBS for Depression

18 - 65
All Sexes
San Diego, CA

Repetitive Transcranial Magnetic stimulation (rTMS) is an FDA-approved therapy for treatment resistant depression (TRD) that involves brief magnetic stimulation pulses on the dorsolateral prefrontal cortex (DLPFC) brain region. But studies of rTMS alone show remission rates of \~30%. Additionally, rTMS has not been shown to improve cognitive functioning that may be an independent factor predicting treatment success. This study will develop a novel multimodal treatment, which combines intermittent theta burst stimulation (iTBS) - a type of rTMS with digital mindfulness training to engage brain plasticity, enhance cognition and alleviate depression symptoms in individuals with TRD.

Phase 2
Recruiting

UC San Diego Health Psychiatry

Image of UF World Equestrian Center in Ocala, United States.

ONE-D TMS + D-Cycloserine for Depression and Concussion

18 - 65
Female
Ocala, FL

Concussion and depression have long been recognized to be intertwined pathologies.1-3 Although female athletes are more likely to suffer from mental health symptoms than males athletes following a concussion,2 research in this area has been largely biased toward males.4 Recently functional MRI (fMRI) studies5 in concussed athletes have established that there are patterns of local alterations in neural connectivity in the frontal cortex that demonstrate anatomic congruency with transcranial magnetic stimulation (TMS) studies that mapped alternations in neural connectivity to functional and somatic symptoms.6 Thus, there is potential that TMS treatment could decrease both symptom profiles, revolutionizing comorbid treatment options. Possible Benefits: Previous studies have showed a 70% remission rate for depression symptoms. It is possible that participants could have improvement in depressive or concussive symptoms after the ONE-D TMS treatment.

Phase 2 & 3
Waitlist Available

UF World Equestrian Center

Sara Gould, MD

Have you considered Sinequan clinical trials?

We made a collection of clinical trials featuring Sinequan, we think they might fit your search criteria.
Go to Trials